Therefore, there is an important need for proapoptotic agents that can sensitize pancreatic ductal adenocarcinoma cells to TRAIL and thereby overcome pancreatic cancer resistance to apoptosis. This evidence concerns the gene TNFSF10 and pancreatic ductal adenocarcinoma.